Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant v. St. Jude

This article was originally published in The Gray Sheet

Executive Summary

Guidant wins appeal from Washington, D.C. federal court to reinstate the validity of a defibrillator patent it claims St. Jude Medical infringed and return the case to the lower court to determine infringement and damages. In February 2002, a federal district court judge overturned a July 2001 jury decision finding St. Jude liable for $140 mil. in damages for infringing Guidant patents (1"The Gray Sheet" Feb. 18, 2002, In Brief)...

You may also be interested in...



Guidant v. St. Jude

Overturned $140 mil. implantable cardiac defibrillator patent infringement damage award to Guidant will likely be appealed, according to St. Jude. Filed by Guidant in November 1996 in Indianapolis federal court, the complaint currently focuses on two Guidant ICD patents ('472 and '288). Judge David Hamilton ruled Feb. 13 that "both patents are invalid," St. Jude says. A jury awarded Guidant the damages in July 2001, after finding that St. Jude infringed the '472 patent, which expired March 4, but that it did not infringe the '288 patent; both had been ruled valid (1"The Gray Sheet" July 9, 2001, In Brief)...

AMS Acquires Raleigh Adhesive Coatings Company For £22M ($29M) In Cash

Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business. 

Amgen Hands Omecamtiv Back To Cytokinetics

While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.

UsernamePublicRestriction

Register

OM005385

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel